Shift From Adalimumab Originator to Biosimilars in Denmark.
other
Where this comes from
- Record sourced from PubMed, PMID 32227137.
- Also identified by DOI 10.1001/jamainternmed.2020.0338 and PMC identifier 7105946.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study describes the nationwide shift from brand-name adalimumab (originator) to adalimumab biosimilars in Denmark and analyzes what a similar shift in the US would look like.
Medical subject headings
- Adalimumab
- Biosimilar Pharmaceuticals
- Drug Costs